Entity linked to Zivo director buys 1,543 shares

Zivo Bioscience director and 10% owner–associated entity buys shares.

Accepted by SEC EDGAR 03/03/2026 - 04:06 PM EST

(Moderate)

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Zivo Bioscience director and 10% owner–associated entity buys shares. An entity associated with director and ten percent owner Laith L. Yaldoo, identified as HEP Investment, LLC, made an open-market purchase of 1,543 shares of Zivo Bioscience common stock at $9.72 per share. After this transaction, the filing reports 583,615 shares of common stock indirectly owned.

Insider Trade Summary

Net Buyer: 1,543 shares

Net Buy 1 txn

Insider YALDOO LAITH L

Role Director, 10% Owner

Bought 1,543 shs ($15K)

Increase in Position 0.27%

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,543	$9.72	$15K

Holdings After Transaction: Common Stock — 583,615 shares (Indirect, HEP Investment, LLC)

Holdings Before and After: Common Stock, 582,072 to 583,615 shares (Indirect, HEP Investment, LLC)

Other Insiders: 1 other insider reported open-market purchases of this stock in the 30 days up to this filing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Zivo Bioscience (ZIVO) report on this Form 4?

Zivo Bioscience reported an open-market purchase of 1,543 common shares. The buying entity is HEP Investment, LLC, which is associated with director and ten percent owner Laith L. Yaldoo, as reflected in the Form 4 insider filing.

Who is the reporting person in the latest Zivo Bioscience (ZIVO) Form 4?

The reporting person is Laith L. Yaldoo, identified as a director and ten percent owner. The purchased shares are held indirectly through HEP Investment, LLC, which is named as the nature of ownership in the Form 4 transaction details.

How many Zivo Bioscience (ZIVO) shares were bought and at what price?

HEP Investment, LLC purchased 1,543 shares of Zivo Bioscience common stock. The Form 4 states the transaction price was $9.72 per share, and the transaction code description identifies it as a purchase in the open market.

What is the total Zivo Bioscience (ZIVO) shareholding after this Form 4 transaction?

Following the reported purchase, total indirectly owned Zivo Bioscience common shares are listed as 583,615. This figure reflects the holdings after the 1,543-share open-market purchase attributed to HEP Investment, LLC on the Form 4.

Was the Zivo Bioscience (ZIVO) insider transaction a buy or a sell?

The transaction was a buy. The Form 4 records transaction code P, describes it as a purchase in the open market, and classifies the direction as an open-market purchase of Zivo Bioscience common stock by HEP Investment, LLC.

Is the Zivo Bioscience (ZIVO) Form 4 transaction direct or indirect ownership?

The ownership is indirect. The Form 4 marks the transaction with ownership code I and specifies the nature of ownership as HEP Investment, LLC, indicating the shares are held through that entity rather than directly by the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

YALDOO LAITH L

(Last)

(First)

(Middle)

1934 BLOOMFIELD DRIVE

(Street)

BLOOMFIELD HILLS

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Zivo Bioscience, Inc. [ ZIVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/27/2026		P		1,543	A	$9.72	583,615	I	HEP Investment, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ Laith L. Yaldoo	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR